We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.37%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$558M
AUM Growth
+$201M
Cap. Flow
+$128M
Cap. Flow %
22.94%
Top 10 Hldgs %
67.51%
Holding
90
New
30
Increased
23
Reduced
7
Closed
26

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$51.2M
2
INDP icon
Indaptus Therapeutics
INDP
+$15M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.24M
5
NVTA
Invitae Corporation
NVTA
+$4.06M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.2M
2
KITE
Kite Pharma, Inc.
KITE
+$7.78M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$5.12M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$4.57M
5
ANAB icon
AnaptysBio
ANAB
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 46.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$94.2M 16.88%
6,737,706
+5,137,706
+321% +$51.2M
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$68.9M 12.35%
465,000
+100,000
+27% +$14.1M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$48.5M 8.69%
560,000
+177,700
+46% +$14.2M
ASMB icon
4
Assembly Biosciences
ASMB
$503M
$34.9M 6.26%
83,333
-2,506
-3% -$768K
VCYT icon
5
Veracyte
VCYT
$3.58B
$28.9M 5.18%
3,295,111
+214,966
+7% +$1.75M
IOVA icon
6
Iovance Biotherapeutics
IOVA
$1.93B
$26.6M 4.77%
3,431,809
+16,765
+0.5% +$106K
INDP icon
7
Indaptus Therapeutics
INDP
$175M
$24.4M 4.37%
1,216
+1,037
+579% +$15M
IRIX icon
8
IRIDEX
IRIX
$14.4M
$18.7M 3.36%
2,000,000
+262,460
+15% +$2.39M
ASND icon
9
Ascendis Pharma A/S
ASND
$16B
$18.1M 3.25%
500,000
-424,483
-46% -$12.2M
PDSB icon
10
PDS Biotechnology
PDSB
$40M
$13.4M 2.41%
62,670
-12,561
-17% -$2.6M
KDMN
11
DELISTED
Kadmon Holdings, Inc.
KDMN
$11.2M 2%
+3,333,333
New +$9.52M
CEMI
12
DELISTED
Chembio diagnostics, Inc.
CEMI
$10.7M 1.91%
1,721,299
+362,948
+27% +$2.23M
IMMU
13
CALL
DELISTED
Immunomedics Inc
IMMU
$9.33M 1.67%
+667,500
New +$6.65M
ZGNX
14
DELISTED
Zogenix, Inc.
ZGNX
$8.76M 1.57%
250,000
-51,700
-17% -$702K
DBVT
15
PUT
DBV Technologies
DBVT
$804M
$8.49M 1.52%
+20,000
New +$8.57M
DBVT
16
DBV Technologies
DBVT
$804M
$8.15M 1.46%
19,200
+8,423
+78% +$3.61M
EVH icon
17
Evolent Health
EVH
$353M
$8.01M 1.44%
450,000
+169,400
+60% +$3.49M
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
$7.67M 1.37%
1,331,983
+645,596
+94% +$3.64M
CLVS
19
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$6.59M 1.18%
+80,000
New +$6.34M
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$4.39B
$6.4M 1.15%
170,000
-80,000
-32% -$2.6M
JNJ icon
21
PUT
Johnson & Johnson
JNJ
$613B
$5.85M 1.05%
45,000
+5,000
+13% +$663K
ZGNX
22
PUT
DELISTED
Zogenix, Inc.
ZGNX
$5.61M 1.01%
160,000
+60,000
+60% +$814K
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.24B
$5.22M 0.94%
996,300
+827,615
+491% +$4.24M
NVTA
24
DELISTED
Invitae Corporation
NVTA
$4.95M 0.89%
528,000
+427,708
+426% +$4.06M
ARGX icon
25
argenx
ARGX
$52B
$4.89M 0.88%
216,255
+63,418
+41% +$1.32M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2017 Portfolio in Review

As of Q3 2017, Acuta Capital Partners held 90 positions worth $558M, up 56% from $357M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Acuta Capital Partners deployed $128M of net new capital in Q3 2017, opening 30 new positions and adding to 23 existing holdings. Its largest new stake was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 60% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $12.2M trimmed.

  • Acuta Capital Partners's largest Q3 2017 buy was Kadmon Holdings, Inc.: 3,333,333 shares worth $11.2M.
  • Acuta Capital Partners added most to Immunomedics Inc in Q3 2017, an estimated $51.2M increase.
  • Acuta Capital Partners's biggest Q3 2017 reduction was Ascendis Pharma A/S, cutting an estimated $12.2M.
  • Acuta Capital Partners fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $7.78M.
  • Acuta Capital Partners's ten largest holdings make up 68% of its $558M portfolio in Q3 2017.
  • Acuta Capital Partners opened 30 new positions and closed 26 in Q3 2017.
  • Acuta Capital Partners's portfolio value rose 56% quarter-over-quarter to $558M.

Based on Acuta Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.